Melvin M. Evers

2.2k citations

39 papers · 1.7k · h-index 22

Impact in

Cellular and Molecular Neuroscience top 2%
- Genetic Neurodegenerative Diseases
Genetics top 5%
- Neurogenetic and Muscular Disorders Research
- Virus-based gene therapy research

Papers in

Molecular Biology 31
- Muscle Physiology and Disorders 10
- Mitochondrial Function and Pathology 10
- RNA Research and Splicing 9
- CRISPR and Genetic Engineering 5
- Ubiquitin and proteasome pathways 4
Cellular and Molecular Neuroscience 23
- Genetic Neurodegenerative Diseases 23

Co-authors: Willeke van Roon‐Mom (9 shared papers)Lodewijk J.A. Toonen (6 shared papers)Pavlina Konstantinova (17 shared papers)S J van Deventer (9 shared papers)Marti F.A. Bierhuizen (1 shared paper)Marc A. Vos (1 shared paper)Martin B. Rook (1 shared paper)Jana Miniarikova (7 shared papers)
Journals: Molecular Therapy — Methods & Clinical Development (5 papers)Neurology (3 papers)Molecular Therapy (2 papers)Nucleic Acid Therapeutics (2 papers)Brain (2 papers)
Partner nations: Netherlands Canada Italy

In The Last Decade

Melvin M. Evers

39 papers receiving 1.6k citations

Peers

Countries citing papers authored by Melvin M. Evers

Since Specialization

Citations

This map shows the geographic impact of Melvin M. Evers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melvin M. Evers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melvin M. Evers more than expected).

Fields of papers citing papers by Melvin M. Evers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melvin M. Evers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melvin M. Evers. The network helps show where Melvin M. Evers may publish in the future.

Co-authors

The 25 scholars most cited alongside Melvin M. Evers, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Melvin M. Evers Line = papers co-authored together Melvin M. Evers links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 39 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Antisense oligonucleotides in therapy for neurodegenerative disorders Advanced Drug Delivery Reviews ·Melvin M. Evers, Lodewijk J.A. Toonen, Willeke van Roon‐Mom	2015	243
2	Biology of cardiac sodium channel Nav1.5 expression Cardiovascular Research ·Martin B. Rook, Melvin M. Evers, Marc A. Vos, Marti F.A. Bierhuizen	2011	163
3	AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington’s Disease Minipig Model Molecular Therapy ·Melvin M. Evers, Jana Miniarikova, Štefan Juhás, Astrid Vallès, Božena Bohuslavová, Jana Juhásová, Helena Kupcová Skalníková, Petr Vodička, Ivona Valeková, Cynthia Brouwers, Bas Blits, Jacek Lubelski, Hana Kovářová, Zdeňka Ellederová, S J van Deventer, Harald Petry, Jan Motlík, Pavlina Konstantinova	2018	130
4	AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington’s disease Gene Therapy ·Jana Miniarikova, Virginie Zimmer, Raygene Martier, Cynthia Brouwers, Catherine Pythoud, Kevin Richetin, M. Rey, Jacek Lubelski, Melvin M. Evers, S J van Deventer, Harald Petry, Nicole Déglon, Pavlina Konstantinova	2017	84
5	Targeting Several CAG Expansion Diseases by a Single Antisense Oligonucleotide PLoS ONE ·Melvin M. Evers, Barry A. Pepers, J.C.T. van Deutekom, Susan Mulders, Johan T. den Dunnen, Annemieke Aartsma‐Rus, Gert‐Jan B. van Ommen, Willeke van Roon‐Mom	2011	84
6	Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy Molecular Therapy — Nucleic Acids ·Raygene Martier, Jolanda M.P. Liefhebber, Ana García‐Osta, Jana Miniarikova, Mar Cuadrado‐Tejedor, María Espelosin, Susana Ursúa, Harald Petry, S J van Deventer, Melvin M. Evers, Pavlina Konstantinova	2019	78
7	Ataxin-3 Protein and RNA Toxicity in Spinocerebellar Ataxia Type 3: Current Insights and Emerging Therapeutic Strategies Molecular Neurobiology ·Melvin M. Evers, Lodewijk J.A. Toonen, Willeke van Roon‐Mom	2013	70
8	Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: Removal of the CAG containing exon Neurobiology of Disease ·Melvin M. Evers, Hoang-Dai Tran, Ioannis Zalachoras, Barry A. Pepers, Onno C. Meijer, Johan T. den Dunnen, Gert‐Jan B. van Ommen, Annemieke Aartsma‐Rus, Willeke van Roon‐Mom	2013	64
9	Transcriptional profiling and biomarker identification reveal tissue specific effects of expanded ataxin-3 in a spinocerebellar ataxia type 3 mouse model Molecular Neurodegeneration ·Lodewijk J.A. Toonen, Maurice Overzier, Melvin M. Evers, Leticia G. León, Sander A.J. van der Zeeuw, Hailiang Mei, Szymon M. Kiełbasa, Jelle J. Goeman, Kristina Hettne, Ólafur Þ. Magnússon, Marion Poirel, Alexandre Seyer, Peter A.C. ’t Hoen, Willeke van Roon‐Mom	2018	63
10	AAV5-miHTT Gene Therapy Demonstrates Sustained Huntingtin Lowering and Functional Improvement in Huntington Disease Mouse Models Molecular Therapy — Methods & Clinical Development ·Elisabeth A. Spronck, Cynthia Brouwers, Astrid Vallès, Martin de Haan, Harald Petry, S J van Deventer, Pavlina Konstantinova, Melvin M. Evers	2019	61
11	Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease Nucleic Acids Research ·Nicholas S. Caron, Amber L. Southwell, Cynthia Brouwers, Louisa Dal Cengio, Yuanyun Xie, Hailey Findlay Black, Lisa M. Anderson, Seung‐Hyun Ko, Xiang Zhu, S J van Deventer, Melvin M. Evers, Pavlina Konstantinova, Michael R. Hayden	2019	59
12	AAV5-miHTT Lowers Huntingtin mRNA and Protein without Off-Target Effects in Patient-Derived Neuronal Cultures and Astrocytes Molecular Therapy — Methods & Clinical Development ·Sonay Keskin, Cynthia Brouwers, Marina Sogorb-González, Raygene Martier, Josse A. Depla, Astrid Vallès, S J van Deventer, Pavlina Konstantinova, Melvin M. Evers	2019	54
13	Preventing Formation of Toxic N-Terminal Huntingtin Fragments Through Antisense Oligonucleotide-Mediated Protein Modification Nucleic Acid Therapeutics ·Melvin M. Evers, Hoang-Dai Tran, Ioannis Zalachoras, Onno C. Meijer, Johan T. den Dunnen, Gert‐Jan B. van Ommen, Annemieke Aartsma‐Rus, Willeke van Roon‐Mom	2013	50
14	Artificial MicroRNAs Targeting C9orf72 Can Reduce Accumulation of Intra-nuclear Transcripts in ALS and FTD Patients Molecular Therapy — Nucleic Acids ·Raygene Martier, Jolanda M.P. Liefhebber, Jana Miniarikova, Tom van der Zon, Jolanda Snapper, I. Kolder, Harald Petry, S J van Deventer, Melvin M. Evers, Pavlina Konstantinova	2019	50
15	Rescue of spinal muscular atrophy mouse models with AAV9-Exon-specific U1 snRNA Nucleic Acids Research ·Irving Donadon, Erica Bussani, Federico Riccardi, Danilo Licastro, Giulia Romano, Giulia Pianigiani, Mirko Pinotti, Pavlina Konstantinova, Melvin M. Evers, Shuo Lin, Markus A. Rüegg, (unknown)	2019	37
16	Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic Molecular Therapy ·Jana Miniarikova, Melvin M. Evers, Pavlina Konstantinova	2018	37
17	Development of an AAV-Based MicroRNA Gene Therapy to Treat Machado-Joseph Disease Molecular Therapy — Methods & Clinical Development ·Raygene Martier, Marina Sogorb-González, Janice Stricker-Shaver, Jeannette Hübener‐Schmid, Sonay Keskin, Jiřı́ Klı́ma, Lodewijk J.A. Toonen, Štefan Juhás, Jana Juhásová, Zdeňka Ellederová, Jan Motlík, Eva Haas, Sander van Deventer, Pavlina Konstantinova, Huu Phuc Nguyen, Melvin M. Evers	2019	36
18	Intrastriatal Administration of AAV5-miHTT in Non-Human Primates and Rats Is Well Tolerated and Results in miHTT Transgene Expression in Key Areas of Huntington Disease Pathology Brain Sciences ·Elisabeth A. Spronck, Astrid Vallès, Margit H. Lampen, Paula S. Montenegro-Miranda, Sonay Keskin, Liesbeth Heijink, Melvin M. Evers, Harald Petry, S. J. H. Van Deventer, Pavlina Konstantinova, Martin de Haan	2021	35
19	Human Brain Organoids as Models for Central Nervous System Viral Infection Viruses ·Josse A. Depla, Lance Mulder, Renata Vieira de Sá, Morgane Wartel, Adithya Sridhar, Melvin M. Evers, Katja C. Wolthers, Dasja Pajkrt	2022	34
20	A Perspective on Organoids for Virology Research Viruses ·Adithya Sridhar, Salvatore Simmini, Carla M. S. Ribeiro, Caroline Tapparel, Melvin M. Evers, Dasja Pajkrt, Katja C. Wolthers	2020	29

About Melvin M. Evers

Melvin M. Evers is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience, Genetics, Genetics and Neurology, having authored 39 papers that have together received 1.7k indexed citations. Recurring topics across this work include Genetic Neurodegenerative Diseases (23 papers), Muscle Physiology and Disorders (10 papers), Mitochondrial Function and Pathology (10 papers), RNA Research and Splicing (9 papers), Neurogenetic and Muscular Disorders Research (5 papers), CRISPR and Genetic Engineering (5 papers), Virus-based gene therapy research (5 papers) and Ubiquitin and proteasome pathways (4 papers). The work is most often cited by research in Cellular and Molecular Neuroscience (698 citations), Genetics (210 citations), Neurology (266 citations), Molecular Biology (1.3k citations) and Cardiology and Cardiovascular Medicine (197 citations). Melvin M. Evers has collaborated with scholars based in Netherlands, Canada and Italy. Frequent co-authors include Willeke van Roon‐Mom, Lodewijk J.A. Toonen, Pavlina Konstantinova, S J van Deventer, Marti F.A. Bierhuizen, Marc A. Vos, Martin B. Rook, Jana Miniarikova, Harald Petry and Cynthia Brouwers. Their work appears in journals such as Molecular Therapy — Methods & Clinical Development, Neurology, Molecular Therapy, Nucleic Acid Therapeutics and Brain.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Melvin M. Evers

Impact in

Papers in i

In The Last Decade

Melvin M. Evers

Peers

Countries citing papers authored by Melvin M. Evers

Fields of papers citing papers by Melvin M. Evers

All Works

About Melvin M. Evers

Explore authors with similar magnitude of impact

Papers in